Public Company News

Analytica have appointed a global heavyweight in the pharmaceutical industry to its board of directors as they gear up for the international launch of an innovative medical device that combats urinary incontinence. Dr Peter B. Corr, the former head of R&D at Pfizer, has joined the Analytica board, strengthening ties he already has as a significant shareholder.

An independent clinical trial of MGC Pharma’s cannabis-based dermatological creams has produced spectacular results with the trials showing an 80% improvement in acne prone skin, 73% improvement in psoriatic plaques, 86% improvement of irritated skin and over 70% improvement in the visual appearance of redness, dryness, flaky and oily skin conditions.

Blackham’s latest round of drilling at Wiluna has produced a best-ever result of 15.4 metres at more than 21 g/t gold, located in a new high-grade shoot that is outside the existing open-pit mine plan. The new drill results revealed much more mineralisation around the old West Pit and make a ‘super pit’ stretching up to 2km a real possibility.

PharmAust’s trials of its promising anti-cancer drug in dogs have produced encouraging early results, reducing the size of tumours in three out of four dogs with no other treatment. The early-stage trials have also shown it will be safe to give dogs significantly higher doses, which could lead to some spectacular results in the next stage of trials.

The rich geology of Hammer Metal’s ground east of Mt Isa has produced yet another happy surprise for the Perth-based explorer —graphite. A recent electromagnetic survey by helicopter highlighted a conductive, graphite-rich bed, with initial samples assaying up to 10% total graphitic carbon.

Stargroup and small tier bank, Goldfields Money, have doubled the size of their partnership, announcing that up to $30 million of Goldfields excess cash would now be made available for Stargroup ATM machines. Goldfields’ banking license coupled with Stargroup’s market penetration conjures up any number of future opportunities for the two ASX listed companies.

Perth-based CVCheck is charging into the black after continued strong revenue growth in April and May. The innovative provider of online police checks, employment screening and a burgeoning range of related products also has more growth in the pipeline, thanks in part to changes to 457 visas in Australia and new requirements by NZ’s Health Department.

Perth listed biotech PharmAust, have determined that their promising anti-cancer drug known as MPL might also be useful in the treatment of diabetes, brain disease and age related disorders. The company announced this week they have secured a patent for MPL in Australia relating to the treatment of the three newly targeted illnesses. 

One of Wall Street’s oldest investment banks has released a bullish assessment of Perth based Northern Minerals, saying Browns Range is among a rare breed of high-value rare earths projects. Hallgarten & Company concluded that Northern Minerals had a project with great metallurgy and set a 12-month price target of 38 cents, a 217% increase over the current levels.

Auroch have begun drilling ahead of schedule in Portugal, just weeks after entering the country with a bold, deep-drilling exploration project targeting high-grade copper and zinc. The first diamond drill hole is expected to take between four and six weeks to test its target, which is just 20kms along strike from the “supergiant” Neves Corvo copper zinc mine.

The marriage of ASX listed Azonto Petroleum to the unlisted Calima Energy is essentially a story of money meets management experience with the marriage consummated at one of the best addresses in town, the Montney oil and gas play in Canada. Calima is the creation of 5 Subiaco based geoscientists who previously took Ophir Energy from an idea to a 2 billion pound company.

Lithium Australia’s Sileach process has given its best indication yet of its breakthrough potential with the latest trials producing 99.8% Lithium Carbonate without the need to roast concentrate. The result was also achieved using a sub-economic grade of just 3.4% Li20 highlighting the potential of Sileach to bring low-grade Lithium deposits to market.